Thrive is a biotech company dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care to extend and save lives.
Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease.
Thrive was founded in 2019 by Kenneth W. Kinzler, Nickolas Papadopoulos and Bert Vogelstein. The company is headquartered in Cambridge, Massachusetts, with an office in Baltimore, Maryland.
Thrive’s vision is to incorporate its blood test, CancerSEEK, into routine medical care and detect more cancers at earlier stages when they can be more effectively treated and, in many cases, cured. CancerSEEK, used in combination with standard-of-care screening tests has the potential to shift this paradigm to a new reality where the majority of cancers, including many with no screening options today, are diagnosed through screening and at earlier stages.
Thrive's blood test more than doubled the number of cancers first detected by screening, enabling better outcomes and, in some cases, potential cure for these patients. The company's approach goes beyond a cancer diagnosis. They are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.
Thrive is backed by Third Rock Ventures, Casdin Capital, Section 32, Bain Capital Life Sciences, Brown Advisory, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures and others. The company raised $257M in Series B round on Jul 29, 2020. This brings Thrive's total funding to $367M to date.